Merck (MRK) Raw Materials (2009 - 2012)
Merck (MRK) reported Raw Materials of $265.0 million for Q2 2012, down 11.07% year-over-year from $298.0 million in Q3 2011, and down 14.52% quarter-over-quarter from $310.0 million in Q1 2012.
Merck (MRK) Raw Materials (2009 - 2012) Analysis & Trends
Merck (MRK) has 4 years of Raw Materials data on file, last reported at $265.0 million in Q2 2012.
- Raw Materials for Q2 2012 came in at $265.0 million, down 11.07% year-over-year; the trailing twelve-month figure through Jun 2012 was $265.0 million (down 11.07% YoY), and the FY2011 annual result was $297.0 million, down 5.71% from the prior year.
- Raw Materials slipped to $265.0 million in Q2 2012 per MRK's latest filing, from $310.0 million in the prior quarter.
- Over five years, Raw Materials peaked at $5.8 billion in Q3 2011 and troughed at $265.0 million in Q2 2012.
- A 4-year average of $1.4 billion and a median of $312.5 million in 2010 frame the typical range for Raw Materials.
- On a YoY basis, Raw Materials climbed as much as 1694.0% in 2011 and fell as far as 94.39% in 2011.
- A 4-year view of Raw Materials shows it stood at $323.0 million in 2009, then slipped by 2.48% to $315.0 million in 2010, then dropped by 5.71% to $297.0 million in 2011, then dropped by 10.77% to $265.0 million in 2012.
- Business Quant data shows MRK's Raw Materials at $265.0 million in Q2 2012, $310.0 million in Q1 2012, and $297.0 million in Q4 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.02 Bn | 107.33 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2012 | 265.00 Mn |
| Mar 31, 2012 | 310.00 Mn |
| Dec 31, 2011 | 297.00 Mn |
| Sep 30, 2011 | 5.80 Bn |
| Jun 30, 2011 | 298.00 Mn |
| Mar 31, 2011 | 306.00 Mn |
| Dec 31, 2010 | 315.00 Mn |
| Sep 30, 2010 | 323.30 Mn |
| Jun 30, 2010 | 5.31 Bn |
| Dec 31, 2009 | 323.00 Mn |